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Title: Prevalence of drug use during sex amongst MSM in 
Europe: results from a multi-site bio-behavioural survey. 
Abstract  
Background 
Substance use has been consistently reported to be more prevalent amongst Men who 
have Sex with Men (MSM) compared to the general population. Substance use, in 
particular polydrug use, has been found to be influenced by social and contextual 
factors and to increase the risk of unprotected intercourse among MSM. The objective 
of this analysis was to investigate the prevalence and predictors of drug use during a 
sexual encounter and to identify specific prevention needs.  
Methods/Design 
A multi-site bio-behavioural cross-sectional survey was implemented in 13 European 
cities, targeting MSM and using Time-Location Sampling and Respondent-Driven 
Sampling methods. Multivariable multi-level logistic random-intercept model 
(random effect of study site) was estimated to identify factors associated with the use 
of alcohol, cannabis, party drugs, sexual performance enhancement drugs and 
chemsex drugs.  
Results 
Overall, 1,261 (30.0%) participants reported drug use, and 436 of 3,706 (11.8%) 
reported the use of two or more drugs during their last sexual encounter. By drug 
class, 966 (23.0%) reported using sexual performance enhancement drugs, 353 (8.4%) 
– party drugs, and 142 (3.4%) the use of chemsex drugs. Respondents who reported 
drug use were more frequently diagnosed with HIV (10.5% vs. 3.9%) before and with 
other STIs during the 12 months prior to the study (16.7% vs. 9.2%). The use of all 
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the analysed substances was significantly associated with sexual encounter with more 
than one partner.  
Discussion  
Substance and polydrug use during sexual encounters occurred amongst sampled 
MSM across Europe although varying greatly between study sites. Different local 
social norms within MSM communities may be important contextual drivers of drug 
use, highlighting the need for innovative and multi-faceted prevention measures to 
reduce HIV/STI risk in the context of drug use.  
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Background  
Substance use has been consistently reported to be more prevalent amongst men who 
have sex with men (MSM) populations compared to the general population (Hunter, 
Dargan, Benzie, White, & Wood, 2014; Mercer et al., 2016; Mor & Davidovich, 
2016; Wohl, Frye, & Johnson, 2008). Studies have addressed legal substances such as 
alcohol or tobacco as well as diverse illegal substances and medications used without 
prescription, the use of the last two refered to as drug use.  
The available literature suggests that patterns of drug use among MSM differ from 
men who report sex with women only (Feaster et al., 2016; Hunter et al., 2014; 
Lhomond, Saurel-Cubizolles, Michaels, & CSF Group, 2014; Wohl et al., 2008). 
Moreover, the evidence also suggests that particular MSM populations may also be 
more likely to use drugs associated with visiting clubs or venues (e.g. cocaine, 
ecstasy, γ-hydroxybutyrate – GHB/ γ-butyrolactone - GBL, hallucinogens, 
methamphetamines)(Feaster et al., 2016; Wohl et al., 2008) and less likely to inject 
opiates (Feaster et al., 2016).  
Substance use amongst MSM has also been shown to be associated with societal 
contextual factors like stigma, poverty, trauma, and, at individual level, internalised 
homophobia, resulting from negative attitudes towards homosexuality in the 
environment (Edelman et al., 2016; Wilson et al., 2016). Perceived stigma towards 
gay/bisexual individuals has also been found to be an important predictor of reduced 
service use, for example reduced HIV testing uptake, of increased risk behaviours and 
poorer mental health (Martinez et al., 2016; Pachankis, Hatzenbuehler, Mirandola, et 
al., 2017; Vanden Berghe, Nöstlinger, & Laga, 2014). The co-occurrence of these 
negative health outcomes can be framed within the emergent approach of syndemics, 
consisting of interacting diseases and the social and environmental factors that 
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promote their negative effects on individuals and populations (Singer, Bulled, 
Ostrach, & Mendenhall, 2017). Syndemics of substance use, depression, and violence 
have been identified amongst MSM (Jie, Ciyong, Xueqing, Hui, & Lingyao, 2012; 
Stall et al., 2003; Vanden Berghe et al., 2014) and could be explained within the 
framework of the minority stress model (Meyer, 2003).  
 
Recent trends in drug use amongst MSM show evolving use patterns specifically 
associated with sex. In this context, several stimulants termed ‘chemsex’ drugs 
(typically mephedrone, GHB/ GBL, and crystallised methamphetamine) appear to be 
increasingly used (Kirby & Thornber-Dunwell, 2013). Chemsex drugs are usually 
taken to prolong sexual pleasure and activity, increase sexual self-confidence as well 
as enhance the perceived quality of sex (Weatherburn, Hickson, Reid, Torres-Rueda, 
& Bourne, 2017). Social and cultural norms in gay subcultures and the party context 
festive scenes may play an important role in explaining the increasing popularity of 
chemsex. For example, they may be related to the supposed ubiquity of chemsex or to 
what it is permitted by or expected from engaging in chemsex (Ahmed et al., 2016).  
 
Substance use amongst MSM, and specifically drug use is a key public health concern 
because it is often associated with sex in specific contexts and may thus be linked to 
the transmission of HIV and other sexually transmitted infections (STIs) (Carey et al., 
2009; Daskalopoulou et al., 2014). Substance use, in particular polydrug use, has been 
found to increase the risk of unprotected anal intercourse or sero-discordant 
unprotected anal intercourse (Daskalopoulou et al., 2014; Santos et al., 2013; Tieu et 
al., 2014). However, there may be differences between the impact of particular 
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substances on risk taking and HIV/STI risk (Carey et al., 2009; Vosburgh, Mansergh, 
Sullivan, & Purcell, 2012).  
 
In Europe, the use of psychoactive substances among MSM in association with sex 
appears to be present consistently, although with different prevalence and patterns 
across the region (Schmidt et al., 2016). Whilst substance use has been described 
amongst MSM for some countries, the patterns of use are poorly understood in other 
countries, in particular in Central- Eastern and Southern Europe. Understanding this 
phenomenon is important in order to improve individual sexual health (e.g. through 
counselling) and to strengthen prevention services for STIs including HIV. This is 
even more so, in view of increasing mobility of MSM in Europe and worldwide and 
risk behaviours, including drug use, undertaken when travelling (Lee, Sullivan, & 
Baral, 2017; Vanden Berghe, Nöstlinger, Hospers, & Laga, 2013). 
The objective of this analysis was to investigate the prevalence and predictors of drug 
use during a sexual encounter amongst MSM. Our focus is on the event-based 
analysis, including sexual partner characteristics and drug use during the same sexual 
encounter. We aim at characterising sexualised drug use in a large community sample 
of MSM who participated in the Sialon II study in 13 cities across Europe, both 
Western and Eastern, in view of specific prevention needs.  
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Methods 
Study design and enrolment 
This multi-site bio-behavioural cross-sectional survey was implemented in 13 
European cities: Brussels (Belgium), Sofia (Bulgaria), Hamburg (Germany), Verona 
(Italy), Vilnius (Lithuania), Warsaw (Poland), Lisbon (Portugal), Bucharest 
(Romania), Bratislava (Slovakia), Ljubljana (Slovenia), Barcelona (Spain), Stockholm 
(Sweden), and Brighton (UK). A detailed description of the study methodology has 
been published elsewhere (Gios et al., 2016). 
Male individuals were enrolled in the study cities during the data collection period in 
line with the following inclusion criteria: having had sex (any kind of sex) with 
another man during the previous 12 months, having provided informed consent, and 
agreed to donate a biological sample (oral fluid or blood depending on the enrolment 
approach adopted in the given city). Anonymous data collection took place from April 
2013 to November 2014.  
Two different data collection methods were used to identify and recruit MSM based 
on formative research conducted in each study site. Time-Location (or time-space) 
sampling (TLS) was used in nine cities (i.e. Brussels, Sofia, Hamburg, Warsaw, 
Lisbon, Ljubljana, Barcelona, Stockholm, and Brighton), whilst Respondent Driven 
Sampling (RDS) was adopted in four cities (Bratislava, Bucharest, Verona, and 
Vilnius).  
In each city, the survey was implemented through trained community field workers 
using the same methodology (adopting study protocols, laboratory algorithms, and 
questionnaires). A target number of 400 MSM per city was planned with an expected 
total of n=5,200 participants for the entire survey. Due to difficulties with RDS 
recruitment in Bucharest, the intended sample size was not reached in Bucharest. 
9 
 
 
Study population 
Overall, a total of 4,901 MSM were surveyed: 3,596 MSM through TLS and 1,305 
through RDS. An extensive description of the study sample characteristics is available 
in the Sialon II bio-behavioural survey report (The Sialon II Project, 2016).  
For the purpose of this analysis, we included only those MSM who reported having 
had anal intercourse with another man during the last six months (N=4,266). Another 
words we analysed only the anal sex events reported for a well-defined time period 
(October 2012 – November 2014). 
 
Instruments 
Questionnaire 
A structured pen-and-paper questionnaire was used to collect self-reported 
behavioural information. The draft questionnaire was translated into the languages of 
the participating countries and piloted before survey implementation. Translations 
were back-translated into English to check consistency. 
 
Laboratory testing of biological samples 
The TLS protocols stipulated that oral fluid (OF) samples were collected and tested 
for HIV antibodies using Genscreen™ HIV 1/2 version 2, BIO-RAD. A total IgG 
antibodies ELISA test Human IgG ELISA Kit 1x96, Quantitative / Immunology 
Consultants Laboratory was used for OF sample testing suitability and quality control. 
All HIV-reactive samples were re-tested with Vironostika HIV Ag/Ab, BioMérieux. 
Samples tested positive to the first ELISA HIV test, but negative to the second were 
classified as negative. Study participants could use their unique personal identifier to 
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receive their test results if they wished. Referral for diagnostic testing and further case 
management was established in line with local procedures. 
 
The RDS survey included pre/post-test counselling in the enrolment and follow-up 
process. Blood samples were collected and serum extracted in line with the local 
standard procedures. Serum samples were tested with a HIV 4th generation 
ELISA/CLIA screening test. A Western Blot test was used to confirm positive cases. 
In case of confirmed HIV positive result, a referral procedure was put in place in line 
with the local standard procedures to ensure proper case management.   
 
Ethics 
Local Ethics Committees approved the study protocols at each study site. The WHO 
Research Project Review Panel (RP2) and successively the WHO Research Ethics 
Review Committee (ERC) approved the protocol prior to data collection.  
 
Variables definition 
Dependent variables 
Self-reported substance use during last anal intercourse with a male partner was 
assessed using the following question: “Before or during your last anal sexual 
intercourse, did you use the following...?” The substances listed included: alcohol, 
poppers, ecstasy, erectile dysfunction medications - Sildenafil/Tadalafil (asked by 
brand names Viagra®/Kamagra/Cialis®), hashish/marijuana, cocaine, amphetamine, 
and GHB//GBL/ketamine. Participants were also asked to provide names of other 
substances which they had used. Possible answers were “yes”, “no”, “prefer not to 
answer”. Missing answers were imputed with “no” and “prefer not to answer” was set 
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to missing, as some participants tended to use this question as a check-box question 
marking only the “yes” answers. The percent of missing answers by substance varied 
between 17.1% and 18.5% with an exception of the two most commonly reported 
substances: alcohol (8.2%) and poppers (14.3%).  
Additionally, summary variables were also created: 1) use of party drugs during the 
last anal sex with a male partner defined as the use of any of MDMA, cocaine or 
amphetamine; 2) use of sexual performance enhancement drugs defined as the use of 
either poppers or erectile dysfunction medication (EDM); 3) use of chemsex drugs 
defined as the use of any of GHB/GBL, ketamine, mephedrone or crystal 
methamphetamine (the last two recoded from the open text question). 
 
Independent variables 
The following independent variables were considered for the analysis: age (calculated 
using the self-reported year of birth), migration status (native: born & live in the study 
country; emigrant: born in the study country & live abroad; immigrant: born abroad & 
live in the study country; visitor: born & live abroad) - recoded in multivariable 
analysis to mobile (emigrant, visitor or immigrant) or native, educational status (up to 
and including secondary school, high school or post-secondary education or 
university/higher), outness (being out about one’s own sexual orientation to majority 
of one’s social network or to less than half of the network members), perceived 
attitudes of parents, at work/school and of friends/ acquaintances towards MSM, 
bisexuality (based on self-reported sexual behaviour in the last six months), self-
reported HIV status, diagnosis of a sexually transmitted infection other than HIV 
(STI) in the past 12 months, having ever injected a drug (lifetime), type of 
partner/partners during the sexual event for which the drug use was recorded (i.e. with 
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a steady partner, with a non-steady partner, with more than one partner), frequenting 
gay venues (the number of times the participant attended any gay venues such as 
social venues, bars, discos, clubs, porn cinemas, cruising areas during past three 
months; recoded for analysis into two categories with the cutting point at median 
value), sexual satisfaction (Likert scale from very satisfied to very unsatisfied 
recorded to very satisfied versus not very satisfied – including all other categories - 
for the analysis). 
  
Data analysis 
The prevalence of use of a substance was defined as the proportion of MSM who 
reported using the substance during the last sexual encounter associated with anal sex 
with another men, among MSM who reported having had an anal intercourse with 
another man within 6 months preceding participation in the study. 
Descriptive statistics, Wilcoxon–Mann–Whitney test, and Kruskal–Wallis test by 
ranks were used for quantitative variables, whilst percentages and Fisher's exact test 
were used for nominal variables.  
Multivariable multi-level logistic random-intercept model (random effect of study 
site) was estimated to account for the hierarchical structure of the data (Rabe-Hesketh, 
Skrondal, & Skrondal, 2008). The multi-level analysis was conducted to identify 
factors associated with the use of alcohol, cannabis, party drugs, sexual performance 
enhancement drugs and chemsex drugs. Predictors associated with the outcome 
variable with a probability <0.05 were considered significant and backwards selection 
was used to identify the most relevant co-variates. Cases with missing values in the 
studied predictors were excluded from the analysis.  
Stata® Version 14.2 was used for all analyses (College Station, TX: StataCorp LP).  
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Results  
Study group characteristics 
In total 4,266 individuals were included in the study. Participants’ median age was 32 
years (interquartile interval 25-40 years), 81.4% lived in the country they were born in 
and, where they were recruited and 55% completed university education (Table 1). A 
large majority (87.3%) reported only male sexual partners in the past six months and 
12.7% reported male and female partners. 
Among the participants, 4,202 (99.4%) provided sufficient information on whether 
they had used any substance at the last anal intercourse with a male partner and 3,706 
(86.8%) - also sufficient to establish the number of substances used. Overall, 1,261 
(30.0%) participants reported drug use, and 436 of 3,706 (11.8%) reported the use of 
two or more drugs during their last sexual encounter. By drug class, 966 (23.0%) 
reported using sexual performance enhancement drugs, 353 (8.4%) – party drugs, and 
142 (3.4%) the use of chemsex drugs. Although drug use was prevalent in all age 
groups, there were differences in age distribution by the class of drug (Fig. 1). Whilst 
the use of sexual performance enhancement drugs increased with age, the use of party 
drugs and chemsex drugs was less prevalent in the older age groups. 
The proportion of men who attained a university degree was generally lower amongst 
those who used drugs (50.9% vs 57.2%) with an exception of those who used 
chemsex drugs of whom 67.2% completed university education (Table 1). The 
proportion of participants who were ‘out’ (i.e. being open about their sexual 
orientation) to the majority of their extended social network was higher in the group 
who had used drugs during the last anal sex (63.8%), especially amongst those who 
used chemsex drugs (84.7%), than amongst those who did not use drugs (55.5%).  
14 
 
Respondents who used drugs more frequently reported to be diagnosed with HIV 
(10.5% vs. 3.9%) (self-reported status)  and to have been diagnosed with another STI 
during the 12 months prior to the study (16.7% vs. 9.2%). Similarly, they were more 
likely to report a history of injecting drugs (7.7% vs. 2.6%). On average, participants 
reported having attended gay venues 18.8 times (median 7) during the past three 
months, but the average was higher (23.7 times, median 11) in the group who used a 
drug during the last sexual encounter. 
Finally, the distribution of partner type differed according to drug use. In the group 
who reported the use of any drug and the group who reported the use of chemsex 
drugs, 12.9% and 22.3% respectively also reported more than one partner during the 
event as opposed to 3.3% in the group who did not use any drug. Those who used 
chemsex drugs more often declared to be very satisfied with their sexual lives (44.2%) 
than those who had not used drugs (31.9%) or had used drugs of other classes. 
Substance use by study site 
Substance use during the last sex differed significantly across the study sites (Table 
2). The most frequently used substances were alcohol reported by 45.2% of 
participants, ranging from 23.8% in Verona to 59.6% in Sofia, and sexual 
performance enhancement drugs reported by 23.1%, ranging from 6.1% in Verona to 
42.9% in Brussels. Other substances were used by less than 10% of the overall 
sample, but with significant variation across cities. Reported party drug use was the 
highest in Brussels (21.2%), Barcelona (15.3%) and Brighton (13.0%), and chemsex 
drug use was the highest in Brussels (13.9%), Brighton (9.3%) and Ljubljana (6.0%). 
Two most commonly observed patterns of drug use were: 1) predominance of poppers 
use (>40% of those who used any drugs used only poppers) in Bratislava, Hamburg, 
Sofia, Stockholm, Vilnius and Warsaw; 2) a large proportion of polydrug use (>20% 
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of those who used any drug used three or more substances) in addition to 20-30% 
using only poppers in Barcelona, Brighton, Brussels, Lisbon and Ljubljana. For 
Lisbon and Verona higher proportion of cannabis were reported. Bucharest had a high 
proportion of missing information on substance use (Supplementary Figure 1).  
 
Predictors of substance use 
The univariable analysis of predictors of substance use is presented in the 
Supplementary Table 1.  
a. Alcohol use 
In the multivariable analysis of alcohol use the significant predictors with the largest 
effect sizes were the sexual encounter with more than one partner vs single steady 
partner (adjusted odds ratio, AOR 2.4, 95%CI 1.7-3.3) and a history of injecting drugs 
(2.0, 1.3-2.9). Younger age, lower education, having had both female and male 
partners vs only male, and frequent visiting of gay venues also predicted alcohol use 
(Table 3). 
b. Cannabis use 
In turn, cannabis use was associated the most with having both male and female 
partners (AOR 3.2, 95%CI 2.2-4.5), being out about sexual orientation to majority of 
the social network (2.5, 1.8-3.4), sexual encounter with more than one partner (2.4, 
1.5-3.8) and having injected drugs in the past (2.5, 1.5-4.1). Other important factors, 
although with smaller effect sizes, included younger age and lower education. 
c. Sexual performance enhancement drugs use 
The odds of use of sexual performance enhancement drugs significantly increased in 
sexual encounters with more than one partner vs one steady partner (AOR 5.6, 95% 
CI 4.0-7.9) and in MSM reporting positive HIV status (2.0, 1.4-2.8). Increased odds 
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of using these drugs were also noted for older ages, lower education, having both 
male and female partners, history of injecting drugs, frequent visiting of gay venues, 
being satisfied with sexual life and an STI diagnosis in the past 12 months. 
d. Party drugs use 
The party drug use strongly correlated with history of injecting drugs (AOR 4.8, 95% 
CI 3.0-7.6) and sexual encounter with more than one partner (3.5, 2.2-5.7), as well as 
being out to the majority of social network (2.0, 1.4-2.8) and having both male and 
female partners (2.2, 1.5-3.2). It was also associated with younger age, being mobile 
(migrant or travelling), negative family attitude towards MSM, frequent attendance at 
gay venues and an STI diagnosis within the past 12 months. 
e. Chemsex drugs use 
The use of chemsex drugs was strongly associated with sexual encounter with more 
than one partner vs one steady partner (AOR 7.4, 95% CI 3.9-14.0), history of 
injecting drugs (5.8, 3.0-11.2) and an STI diagnosis in the past 12 months (3.0, 1.8 – 
5.1). Younger age and university education predicted chemsex use as well. 
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Discussion  
Our results quantify the frequency of substance use during sexual encounters amongst 
MSM sampled in study sites across Europe. Alcohol was the most commonly reported 
substance used by nearly half of the participants. Drug use, most commonly sexual 
performance enhancement drugs use, was reported in less than a third of anal sex 
events.  
It is important to underline that the data collected for this behaviour referred to the last 
sexual encounter. Clearly, this estimate is not directly comparable with the proportion 
of MSM who use drugs in general, be it during sex or in other contexts. Moreover, the 
proportion of sexual encounters, during which MSM use substances can be interpreted 
in the context of the frequency of sexual encounters in this group. A study in U.S. 
established that MSM engaged in an estimated average of 81 sex acts per year (Wall, 
Stephenson, & Sullivan, 2013). Thus, although possibly using drugs on two different 
encounters is correlated it is still very likely that asking about drug use at sex during a 
three/six-month period would yield a higher estimate of the proportion of MSM, who 
report this behaviours.  
Nevertheless, the relative frequency of using these substances established in our study 
is consistent with the results of prior studies in Europe and in the US, which collected 
information on use during the past six months (Feaster et al., 2016; Schmidt et al., 
2016). One notable exception is cannabis, which was relatively more common in 
these studies than in ours. Because our study asked specifically about the use before 
or during sex, this may indicate that in this study population cannabis is less used in 
sexual contexts in contrast to other social situations.  
Prevalence of drug use, including the different types of drugs used, varied greatly 
across the study cities. The use of any drug ranged from 12.9% in Vilnius to 52.9% in 
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Brussels. Although there is a substantial variation between the different study sites as 
to the particular substances used, we note that poppers as a single substance or in 
combination with alcohol were the most commonly used substances. Polysubstance 
use is quite frequent, given that in 4 out of 13 study sites using three or more 
substances (excluding alcohol) accounted for over 20% of all sexual encounters 
associated with substance use. To some extent these differences may be related to the 
characteristics of the participants recruited in different study locations. However, we 
note that even in the multivariable models the (random) effect of the city remained 
significant. This draws attention to different social or sub-cultural norms related to 
drug use within the studied populations, as observed in a prior study (Chard, Metheny, 
Sullivan, & Stephenson, 2017). Moreover, the observed differences may be related to 
differences in supply, prices and availability of particular substances on the local 
markets. Data collated by the European Monitoring Centre for Drugs and Drug 
Addictions (http://www.emcdda.europa.eu/data/stats2017) indicate substantial 
diversity in terms of drug prices and prevalence of use between various European 
countries. 
The demographic predictors of drug use identified in our models include age and 
education. In line with our results younger age was previously described as a predictor 
of drug use, especially chemsex and polysubstance use (Daskalopoulou et al., 2014; 
Schmidt et al., 2016; Sewell et al., 2017). In addition, we identified older age as 
predictor of increased use of sexual performance enhancement drugs, which points to 
differential patterns of drug use by age. University education predicted less alcohol 
and drug use in our study, with exception of chemsex drugs, which were in fact more 
prevalent among the university graduates. The prior findings on the role of university 
education are mixed. Some studies report higher drug use amongst less educated 
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MSM (e.g. (Sewell et al., 2017)). In others, university education predicted in e.g. 
higher prevalence of polysubstance use (Daskalopoulou et al., 2014) or education was 
not associated to chemsex (Glynn et al., 2018). As indicated also by our results, the 
effect could differ depending on the particular drugs studied. 
 
In our study MSM who also have sex with women (MSMW) showed increased odds 
of substance use with the largest effect sizes for cannabis and party drug use. There is 
prior evidence that this sub-population of MSM can have specific patterns of drug use 
in general (Lhomond et al., 2014). MSMW not only represent a sub-population of 
MSM with specific needs, but also with different access to services such as HIV 
screening, with increased odds of both less recent test seeking behaviour and lifetime 
HIV testing (Mirandola, Gios, Davis, et al., 2017; Mirandola, Gios, Sherriff, et al., 
2017).  
Generally, amongst specific MSM subpopulations like MSMW, but also migrant 
MSM, overlapping or dual stigma plays a key role in providing further insight of risky 
behavioural patterns (Mirandola, Gios, Davis, et al., 2017; Mirandola, Gios, Sherriff, 
et al., 2017; Pachankis, Hatzenbuehler, Berg, et al., 2017). In our study, being a 
migrant predicted party drug use and alcohol use, but the difference with respect to 
the native population was small.  
“Outness” appeared to have an enhancing effect on the use of party drugs, chemsex 
drugs and cannabis in our study. This is unexpected given that concealment has been 
shown to increase the odds of sexual risk behaviours and suboptimal service use in a 
recent study (Pachankis et al., 2015). However, drug use was not specifically 
investigated in that study and the association of “outness” with increased drug use is 
in fact supported in other studies (Petersson, Tikkanen, & Schmidt, 2016). This 
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relationship could be mediated through attendance at sex parties. Previous research 
demonstrated the high prevalence of chemsex use during sex parties in public venues 
(especially gay venues) and was found to be even higher amongst those attending 
private sex parties (Schmidt et al., 2016). While we corrected in our model for higher 
attendance in gay venues, we did not have sufficient information about private party 
attendance.  
Drug use was also associated with the type of sexual partner(s). In fact, sexual 
encounters were more closely related to drug use when more than one sexual partner 
was involved. Group sex indicated an almost six-times higher chance of using sexual 
performance enhancement drugs and increased over seven times the chances of using 
chemsex drugs. This is in line with previous studies associating drug use with sex 
parties and with multiple partners during sexual encounter (Ahmed et al., 2016; Ober, 
Shoptaw, Wang, Gorbach, & Weiss, 2009). MSM reporting group sex have been 
found to exhibit higher sexual risk and polysubstance use. They were also more likely 
to suffer from psychosocial problems, supporting evidence of syndemic effect 
(Hirshfield et al., 2015). 
 
Perceived negative attitudes towards gay and bisexuals, as measured in different 
contexts (at work/school, amongst friends, family and parents), did not correlate with 
the reported drug use, with the only exception of parental/ family negative attitudes 
increasing the risk of party drug use. These findings do not fully support  the general 
syndemic theory, in line with which the negative social attitudes may result in 
minority stress, internalized homonegativity and, in consequence, the co-occurrence 
of mental health problems, including substance use and increased risk taking 
(Martinez et al., 2016; Pachankis, Hatzenbuehler, Mirandola, et al., 2017; Vanden 
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Berghe et al., 2014). However, also the results of the prior research on syndemics 
related specifically to substance use are mixed. Some studies suggest that drug use 
among MSM is a strategy to cope with HIV diagnosis, internalised homonegativity, 
and depression (Edelman et al., 2016). On the other hand it has been also indicated 
that minority stress may be rather associated with substance dependence and less so 
with recreational substance use (Lea, de Wit, & Reynolds, 2014). This last finding 
corresponds to our results, as we studied the recreational use, not referring to 
dependence and/or problem drug use. In addition, other research indicates that 
recreational drug use may be driven by local social norms (Chard et al., 2017), 
especially those associated with specific social spaces, clubs or sex-parties (Ahmed et 
al., 2016; Mereish, Goldbach, Burgess, & DiBello, 2017). We found that being ‘out’ 
and frequently attending gay venues increased chances of alcohol and drug use during 
the last sexual encounter, which indirectly supports the importance of these norms.  
Enhancing sexual experience was identified as one of the motivations for sex-related 
drug use (Bourne, Reid, Hickson, Torres Rueda, & Weatherburn, 2014; Weatherburn 
et al., 2017). In our multivariable models being very satisfied with one’s sexual life 
was significantly associated with sexual performance enhancement drug use. 
However, the univariable effect was the strongest for chemsex drugs. It was not 
significant in the multivariable model, possibly due to smaller number of respondents 
reporting chemsex drug use. 
Finally, even if injecting drugs in the past was only reported by small minority of our 
respondents (4.4%), our study confirmed strong correlations between having ever 
injected a drug and drug use during sex. Injection history was associated with 
approximately five times higher odds of party drug use and almost six times higher 
odds of chemsex drugs use. As noted by Glass et al. (Glass, Hope, Tanner, & Desai, 
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2017) injecting drugs associated with sexualised drug use (‘slamming’) may be on the 
increase. Although we did not collect information on whether or not injecting took 
place in the context of sexual encounters, we note that at least the subgroups of MSM 
who inject drugs and MSM who practice chemsex overlap. 
 
Limitations 
There are possible pitfalls in interpreting the results of our study. Firstly, drug use and 
other covariates were measured through a self-administered questionnaire, which 
carries the risk of incorrect or incomplete reporting. While anonymity may have 
mitigated this effect to a certain extent, we cannot exclude the possibility of recall bias 
and that participants may have underreported substance use due to social desirability 
or misinterpretation of the questions. This could be especially true for ‘chemsex’ 
drugs as the use of mephedrone and crystal methamphetamine was not asked directly, 
but established based on an open text field. Adopting a community-based approach in 
collaboration with trustful community organisations to reach different groups of 
MSM, potentially contributed to reducing social desirability biases. 
A second limitation is related to the sampling methodology. TLS and RDS methods 
are considered quasi-probabilistic approaches, targeting only those MSM associated 
with specific MSM communities either through their attendance in gay venues (TLS) 
or through personal social network (RDS). These approaches are subject to specific 
drawbacks, including possible over- or under-representation of potential MSM sub-
samples (Kendall et al., 2008). Additionally, the difficulties with RDS recruitment in 
Bucharest could have affected the sample representativeness and the estimates’ 
precision in this city. Nonetheless, the adopted methods represent a benchmark in bio-
behavioural surveys and allow reaching wide representation of the target population. 
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Finally, findings of this analysis should not be directly generalised to all European 
MSM, as it is not possible to exclude the influence of unmeasured common patterns 
or contextual factors (such as cultural variations, social norms) not taken into account 
in this study design. Nevertheless, as the study succeeded in recruitment of a large 
number of participants across diverse settings in Europe, it offers a pan-European 
perspective.  
 
Conclusions  
We found that drug use before or during sexual encounters occurs among MSM in all 
studied sites in Europe, although it appears relevant only for a fraction of MSM. 
While some common predictors were established for all classes of drugs, some 
important differences found in this study underline the complexity of drug use 
amongst MSM. The differentiated patterns of drug use between the study sites draw 
attention to these populations’ specific needs and call for innovative and multi-faceted 
prevention measures to reduce of HIV/STI risk in the context of drug use adapted to 
local contexts. Although some studies have highlighted the potential role of drug use, 
particularly ‘chemsex’, in facilitating the adoption of sexual risk behaviours (e.g. 
UAI) amongst MSM, by reducing behavioural control when under the influence of 
drugs (Bourne et al., 2014), the causal relationship is debatable (Digiusto & 
Rawstorne, 2013; Edelman et al., 2016; Melendez-Torres & Bourne, 2016). Referring 
to syndemics’ theory, both risky behaviour and drug use may be related to social 
environments stigmatising towards gay and bisexual men (Martinez et al., 2016; 
Santos et al., 2014; Vanden Berghe et al., 2014).  
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Consequently, new intervention models underline tailoring the measures to individual 
profiles, considering possible co-existing conditions, such as depression, potentially 
mediating drug use and risky behaviours (Achterbergh, van der Helm, van den Brink, 
& de Vries, 2017; Fletcher & Reback, 2015). Taking on a harm-reduction approach 
and the implementation of outpatient drug use counselling within LGBTI-focused 
services was shown to be successful in terms of both reduced drug-use and improved 
psychosocial outcomes (Lea et al., 2017). These could include the STI/HIV 
community based services, which may attract MSM who do not perceive drug use as 
their particular problem. Community-based approaches including outreach may also 
be of value, changing individual behaviour through targeting social and community 
norms (Lauby et al., 2017). Our main findings confirm that local social norms within 
MSM communities may be important contextual drivers of drug use among MSM. 
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Table 1. Characteristics of the study population, including total population and by drug used during last sexual encounter associated with anal 
sex, Sialon II. 
  
Total No drug 
reported 
Any drug 
reported 
Sexual 
performa
nce drug 
reported 
Party 
drug 
reported 
Chemsex 
drug 
reported 
Alcohol 
reported 
Cannabis 
reported 
Total  4266 2941 1261 966 353 142 1904 331 
Age (years) mean/SD; median (IQR) 33.7/10.7; 
32 (25-40) 
33.4/10.6;31 
(25-39) 
34.6 (10.8); 
33 (26-42) 
35.7/10.9;
34 (27-43) 
32.2/9.1; 
32 (22-40) 
32.2/8.7; 32 
(25-37) 
32.4/9.8; 30 
(25-38) 
30.9/9.8; 
29 (23-36) 
          
Age group 18-24 887 (20.8) 643 (21.9) 232 (18.4) 142 (14.7) 75 (21.3) 30 (21.1) 433 (22.8) 102 (30.8)  
25-34 1698 (39.8) 1171 (39.9) 497 (39.4) 381 (39.4) 156 (44.3) 64 (45.1) 833 (43.8) 134 (40.5)  
35-44 989 (23.2) 688 (23.4) 286 (22.7) 236 (24.4) 80 (22.7) 34 (23.9) 390 (20.5) 56 (16.9)  
45-54 483 (11.3) 302 (10.3) 177 (14.0) 146 (15.1) 36 (10.2) 13 (9.2) 183 (9.6) 32 (9.7)  
55+ 205 (4.8) 134 (4.6) 68 (5.4) 61 (6.3) 5 (1.4) 1 (0.7) 64 (3.4) 7 (2.1) 
  Missing 4  3  1  0  1  0  1  0  
          
Migration Status native: born & live in the study country 3463 (81.4) 2408 (82.0) 996 (79.4) 765 (79.7) 255 (73.1) 96 (68.6) 1531 (80.7) 259 (78.2)  
emigrant: born in the study country & 
live abroad 
55 (1.3) 37 (1.3) 18 (1.4) 11 (1.1) 4 (1.1) 2 (1.4) 29 (1.5) 5 (1.5) 
 
immigrant: born abroad & live in the 
study country 
520 (12.2) 348 (11.9) 169 (13.5) 127 (13.2) 67 (19.2) 25 (17.9) 233 (12.3) 48 (14.5) 
 
visitor: born & live abroad 214 (5.0) 142 (4.8) 71 (5.7) 57 (5.9) 23 (6.6) 17 (12.1) 105 (5.5) 19 (5.7) 
  Missing 14  6 7  6  4  4  6 0  
          
Education secondary or lower 268 (6.4) 159 (5.5) 101 (8.2) 68 (7.2) 43 (12.7) 6 (4.4) 131 (7.0) 47 (14.8)  
high school or post secondary education 
(vocational school or college) 
1610 (38.6) 1075 (37.3) 502 (40.9) 372 (39.2) 131 (38.6) 39 (28.5) 744 (40.0) 139 (43.7) 
 
university studies or degree 2295 (55.0) 1650 (57.2) 625 (50.9) 509 (53.6) 165 (48.7) 92 (67.2) 987 (53.0) 132 (41.5) 
  Missing 93  57  33  17  14  5  42  13  
          
Outness out to less than half 1737 (42.1) 1261 (44.5) 448 (36.2) 337 (35.5) 114 (33.2) 21 (15.3) 784 (42.1) 94 (28.9)  
out to majority 2385 (57.9) 1571 (55.5) 789 (63.8) 612 (64.5) 229 (66.8) 116 (84.7) 1077 (57.9) 231 (71.1) 
  Missing 144  109  24  17  10  5  43  6 
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Attitude towards 
MSM at work/school 
Negative 1195 (29.1) 842 (29.8) 333 (27.1) 240 (25.6) 94 (27.6) 29 (21.0) 557 (30.0) 83 (25.4) 
 
neutral or positive 2916 (70.9) 1987 (70.2) 895 (72.9) 698 (74.4) 247 (72.4) 109 (79.0) 1300 (70.0) 244 (74.6)  
Missing 155  112  33  28  12  4  1857  327  
          
Attitude towards 
MSM by parents  
Negative 1161 (28.9) 824 (29.9) 320 (26.5) 228 (24.6) 101 (30.6) 27 (20.1) 523 (28.7) 77 (23.9) 
 
neutral or positive 2850 (71.1) 1933 (70.1) 886 (73.5) 698 (75.4) 229 (69.4) 107 (79.9) 1298 (71.3) 245 (76.1) 
  Missing 255  184  55  40  23  8  83  9  
          
Attitude towards 
MSM by 
friends/acquaintances 
Negative 315 (7.8) 218 (7.8) 88 (7.3) 63 (6.8) 27 (8.2) 4 (3.0) 146 (7.9) 24 (7.5) 
 
neutral or positive 3741 (92.2) 2582 (92.2) 1120 (92.7) 870 (93.2) 301 (91.8) 131 (97.0) 1691 (92.1) 296 (92.5)  
Missing 210  141 53  33  25  7  67  11  
          
Declared HIV status 
independent of test 
result 
HIV positive 253 (5.9) 116 (3.9) 132 (10.5) 116 (12.0) 43 (12.2) 25 (17.6) 121 (6.4) 28 (8.5) 
 
HIV negative 3154 (73.9) 2200 (74.8) 931 (73.8) 720 (74.5) 255 (72.2) 109 (76.8) 1440 (75.6) 235 (71.0)  
Other 859 (20.1) 625 (21.3) 198 (15.7) 130 (13.5) 55 (15.6) 8 (5.6) 343 (18.0) 68 (20.5)  
Missing 0  0  0  0  0  0  0  0  
          
Relationships with 
women and men, last 6 
months 
male only 3499 (87.3) 2461 (89.2) 1016 (84.0) 799 (86.5) 263 (78.5) 119 (87.5) 1571 (85.4) 240 (75.9) 
 
female and male partners 508 (12.7) 299 (10.8) 193 (16.0) 125 (13.5) 72 (21.5) 17 (12.5) 269 (14.6) 76 (24.1) 
  Missing 259  181  52  42  18  6  64  15  
          
Ever injected drugs No 3681 (95.6) 2639 (97.4) 1016 (92.3) 793 (93.5) 242 (83.7) 89 (80.2) 1628 (94.1) 262 (90.3)  
Yes 168 (4.4) 71 (2.6) 85 (7.7) 55 (6.5) 47 (16.3) 22 (19.8) 102 (5.9) 28 (9.7)  
Missing 417  231  160  118  64  31  1730  290  
          
Diagnosis of STIs in 
the last 12 months 
No 3774 (88.5) 2671 (90.8) 1051 (83.3) 791 (81.9) 281 (79.6) 104 (73.2) 1644 (86.3) 281 (84.9) 
 
Yes 492 (11.5) 270 (9.2) 210 (16.7) 175 (18.1) 72 (20.4) 38 (26.8) 260 (13.7) 50 (15.1) 
  Missing 0  0  0  0  0  0  0  0 
          
Satisfaction with own 
sexual life 
Not very satisfied 2708 (67.8) 1870 (68.1) 822 (67.8) 617 (66.0) 212 (63.3) 77 (55.8) 1291 (70.4) 207 (66.1) 
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Very satisfied 1286 (32.2) 877 (31.9) 390 (32.2) 318 (34.0) 123 (36.7) 61 (44.2) 543 (29.6) 106 (33.9)  
Missing 272  194  49  31  18  4  70 18  
          
Last anal intercourse 
with 
steady partner 1873 (47.6) 1398 (51.8) 457 (38.1) 337 (36.6) 127 (38.6) 52 (40.0) 760 (41.8) 133 (42.4) 
 
non-steady partner 1813 (46.1) 1212 (44.9) 587 (49.0) 443 (48.1) 149 (45.3) 49 (37.7) 899 (49.5) 145 (46.2)  
more than one partner 246 (6.3) 89 (3.3) 154 (12.9) 141 (15.3) 53 (16.1) 29 (22.3) 158 (8.7) 36 (11.5)  
Missing 334  242  63  45  24  12  87  17  
    
      
  
Number of gay venues 
attended during the 
past 3 months 
mean/SD; median (IQR) 18.8/42.2; 7 
(2-20) 
16.7/39.9; 6 
(2-17) 
23.7/46.9;11 
(3-26.5) 
22.9/48.1; 
11 (1-25) 
29.9/49.0; 
15 (5-34) 
25.3/33.7;13
.5 (4.5-28.5) 
22.9/48.9; 
10 (3-25) 
25.3/50.5; 
10 (3-29) 
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Table 2. Substance use during last sexual encounter associated with anal intercourse, by study site, Sialon II 
Study site 
Any 
substance 
(n,%)* 
Any drug 
(n,%) 
Alcohol 
(n,%) 
Cannabis 
(n,%) 
Pperformanc
e drugs (n,%) 
Party drugs 
(N,%) 
Chemsex 
drugs  
(n,%) 
Number of 
substances 
among those 
who used any 
(mean/SD, 
median (IQR) 
Barcelona 198(55.9) 135(38.1) 146(41.2) 56 (15.8) 101 (28.5) 54 (15.3) 16 (4.5) 2.1/1.6, 1(1-2) 
Bratislava 172(50.4) 78(22.9) 133(39.0) 23 (6.7) 67 (19.6) 9 (2.6) 1 (0.3) 1.4/.7, 1(1-2) 
Brighton 218(67.7) 138(42.9) 179(55.6) 23 (7.2) 120 (37.3) 42 (13.0) 30 (9.3) 2.0/1.4, 2(1-3) 
Brussels 243(71.5) 180(52.9) 179(52.6) 39 (11.5) 146 (42.9) 72 (21.2) 47 (13.9) 2.3/1.6, 2(1-3) 
Bucharest 74(48.1) 25(17.7) 68(45.3) 8 (5.9) 11 (8.3) 13 (8.4) 0 (0.0) 1.4/.8, 1(1-2) 
Hamburg 192(58.7) 115(35.2) 157(48.0) 26 (8.0) 99 (30.3) 17 (5.2) 4 (1.2) 1.7/1.0, 1(1-2) 
Lisbon 159(44.2) 81(22.5) 120(33.3) 28 (7.8) 48 (13.4) 19 (5.3) 7 (1.9) 1.5/1.0, 1(1-2) 
Ljubljana 184(54.9) 92(27.5) 154(46.0) 40 (12.0) 59 (17.6) 29 (8.7) 20 (6.0) 1.8/1.4, 1(1-2) 
Sofia 270(65.7) 146(35.7) 245(59.6) 23 (5.6) 103 (25.3) 42 (10.2) 2 (0.5) 1.6/.7, 1(1-2) 
Stockholm 122(41.9) 59(20.3) 95(32.6) 4 (1.4) 54 (18.6) 9 (3.1) 1 (0.3) 1.5/.9, 1(1-2) 
Verona 112(31.2) 56(15.6) 85(23.8) 33 (9.2) 22 (6.1) 16 (4.5) 3 (0.8) 1.5/1.0, 1(1-2) 
Vilnius 158(55.2) 37(12.9) 151(52.8) 9 (3.1) 30 (10.5) 7 (2.4) 1 (0.3) 1.3/.9, 1(1-1) 
Warsaw 223(66.4) 119(35.4) 192(57.5) 19 (5.7) 106 (31.5) 24 (7.1) 10 (3.0) 1.7/1.1, 1(1-2) 
Total 2325(55.1) 1261(30.0) 1904(45.2) 331 (7.9) 966 (23.1) 353 (8.4) 142 (3.4) 1.7/1.2, 1(1-2) 
p-value for 
difference 
between 
sites 
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
* percent calculated with respect to non-missing observations 
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Table 3. Factors related to substance use during last sexual encounter associated with anal sex, by substance type. Results of multivariable analysis, Sialon II 
    Party drugs   Performance drugs Chemsex drugs   Alcohol   Cannabis   
    Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Age (per 10 years 
increase) 
0.98 (0.97-1) 0.046 1.02 (1.01-1.03) 0.000 0.95 (0.93-
0.97) 
0.000 0.98 (0.97-0.99) 0.000 0.97 (0.95-0.98) 0.000 
            
Migration status Mobile 1.6 (1.1-2.3) 0.010 -# 
 
- 
 
1.5 (1.2-1.8) 0.000 - 
 
 
Native Ref. 
     
Ref. 
   
            
Education University 0.7 (0.5-0.95) 0.022 0.8 (0.7-0.9) 0.008 1.8 (1.1-2.9) 0.016 0.82 (0.7-0.95) 0.009 0.6 (0.5-0.8) 0.000  
Lower Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
            
Outness Out to majority 2.0 (1.4-2.8) 0.000 - 
 
2.3 (1.3-4.2) 0.005 - 
 
2.5 (1.8-3.4) 0.000  
Out to less 
than half 
Ref. 
   
Ref. 
   
Ref. 
 
            
Attitude towards 
MSM by 
parents/family 
Negative 1.4 (1.1-2.0) 0.025 - 
 
- 
 
- 
 
- 
 
 
Neutral or 
positive 
Ref. 
         
            
Self-reported HIV 
status 
Diagnosed with 
HIV 
- 
 
2.0 (1.4-2.8) 0.000 - 
 
- 
 
- 
 
 
Not diagnosed 
with HIV 
  
Ref. 
       
            
            
Relationships with 
women and men, 
last 6 months 
female and 
male  
2.2 (1.5-3.2) 0.000 1.4 (1.0-1.8) 0.023 - 
 
1.5 (1.2-1.8) 0.001 3.2 (2.2-4.5) 0.000 
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    Party drugs   Performance drugs Chemsex drugs   Alcohol   Cannabis   
    Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value  
male only Ref. 
 
Ref. 
   
Ref. 
 
Ref. 
 
            
Partner during last 
anal sex 
One non-
steady 
1.2 (0.9-1.6) 0.257 1.5 (1.2-1.8) 0.000 1.2 (0.7-1.9) 0.591 1.5 (1.3-1.7) 0.000 1.1 (0.8-1.4) 0.756 
 
More than one 
partner 
3.5 (2.2-5.7) 0.000 5.6 (4.0-7.9) 0.000 7.4 (3.9-14) 0.000 2.4 (1.7-3.3) 0.000 2.4 (1.5-3.8) 0.000 
 
One steady 
partner 
Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
            
Having ever 
injected drug 
Yes 4.8 (3.0-7.6) 0.000 1.8 (1.2-2.7) 0.009 5.8 (3.1-15) 0.000 2.0 (1.3-2.9) 0.001 2.5 (1.5-4.1) 0.000 
 
No Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 
            
Visiting gay venues 
within the last 3 
months 
≥7 times 1.6 (1.1-2.2) 0.009 1.3 (1.1-1.6) 0.005 - 
 
1.7 (1.4-2.0) 0.000 - 
 
 
<7 times Ref. 
 
Ref. 
   
Ref. 
   
            
Satisfaction with 
sexual life 
Very satisfied - 
 
1.2 (1.0-1.5) 0.044 - 
 
- 
 
- 
 
 
Not very 
satisfied 
  
Ref. 
       
            
STI diagnosis, past 
12 months 
Yes 1.6 (1.1-2.4) 0.009 1.7 (1.3-2.2) 0.000 3.0 (1.8-5.1) 0.000 - 
 
- 
 
 
No Ref. 
 
Ref. 
 
Ref. 
     
city (random effect 
variance) 
0.4 (0.1-1.04)   0.4 (0.2-0.9)   2.1 (0.8-5.9)   0.2 (0.1-0.5)   0.2 (0.1-0.7)   
*multivariable logistic regression with random effect of city. LR test vs logistic p<0.0001; # “-“ indicates that the variable was not included in the final model for a given 
dependent variable. 
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Figure 1. Party drug, sexual performance enhancement and chemsex drug use before or during last anal sex, by drug class, Sialon II 
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Supplementary Table 1. Intermediate results for the analysis of predictors of use of difference substances: A. Results of univariable logistic 
regression models; B. Results of random effect logistic regression models (city random effect) with use of different substances as dependant 
variables, Sialon II 
 Dependant variable: 
Independent variables: Alcohol Cannabis 
Sexual 
performance 
drugs (poppers, 
EDM**) 
Party drugs 
(cocaine, 
amphetamine, 
MDMA) 
Chemsex drugs 
(GHB, ketamine, 
mephedrone)  
More than 1 
substance 
      
A. Univariable analysis       
       
Age (per year) 0.98*** 0.97*** 1.02*** 0.98** 0.99 1.0 
Mobile vs native# 1.1 1.2 1.1 1.7*** 2.0*** 1.5*** 
University education vs. lower 0.9* 0.5*** 0.9 0.8* 1.7** 0.8 
Out to majority vs. out to less than half 1.0 1.9*** 1.4*** 1.5*** 4.1*** 2.2*** 
Neutral positive attitude of work/schoolmates vs 
negative 0.7 1.2 1.2* 1.1 1.6* 1.5*** 
Neutral positive attitude of parents/family vs 
negative 1.0 1.3* 1.3** 0.9 1.6* 1.3* 
Neutral positive attitude of friends vs negative 1.0 1.0 1.2 0.9 2.8* 1.6* 
Self-reported HIV positive vs self-reported 
negative 1.1 1.6* 3.0*** 2.3*** 3.1*** 3.7*** 
Self-reported HIV indetermined vs self-reported 
negative 0.8* 1.1 0.6*** 0.8 0.3*** 0.7* 
Having had a female vs only male partners 1.4*** 2.5*** 1.2 2.0*** 1.0 1.7*** 
Last anal sex event - non-steady partner 1.4*** 1.1 1.5*** 1.2 1.0 1.2 
A. Cont.       
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 Dependant variable: 
Independent variables: Alcohol Cannabis 
Sexual 
performance 
drugs (poppers, 
EDM**) 
Party drugs 
(cocaine, 
amphetamine, 
MDMA) 
Chemsex drugs 
(GHB, ketamine, 
mephedrone)  
More than 1 
substance 
      
Last anal sex event - more than one partner 2.7*** 2.3*** 6.2*** 3.8*** 4.7*** 6.5*** 
Having ever injected drug 2.1*** 2.9*** 2.1*** 5.5*** 6.8*** 4.7*** 
Visiting gay venues last 3 months (≥7 times vs <7 
times) 1.7*** 1.4** 1.6*** 2.3*** 2.2*** 1.9*** 
Being very satisfied with sexual life 0.8** 1.1 1.1 1.2 1.7** 1.3*** 
STI diagnosis in the past 12 months 1.4*** 1.4* 2.1*** 2.1*** 3.0*** 2.3*** 
       
B. Multiviariable logistic regression models with city random effect    
    
Age (per year) 0.98*** 0.97*** 1.02*** 0.98* 0.95*** 0.99 
Mobile vs native# 1.48*** 1.26 1.08 1.55* 1.53 1.48* 
University education vs. lower 0.79** 0.63** 0.78** 0.71* 1.80* 0.70* 
Out to majority vs. out to less than half 1.08 2.46*** 1.13 1.85*** 2.92** 2.03*** 
Neutral positive attitude of work/schoolmates vs 
negative 0.86 1.01 1.00 1.10 0.89 1.16 
Neutral positive attitude of parents/family vs 
negative 1.10 1.17 sty.18 0.67* 0.78 0.86 
Neutral positive attitude of friends vs negative 0.94 1.17 0.70 0.86 2.79 1.22 
Self-reported HIV positive vs self-reported 
negative 1.05 1.02 2.10*** 1.26 1.79 2.27*** 
Self-reported HIV undetermined vs self-reported 
negative 1.24* 1.20 0.88 0.91 0.19* 0.93 
B. Cont.       
Having had a female vs only male partners 1.39** 3.63*** 1.37* 2.09*** 1.89 2.52*** 
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 Dependant variable: 
Independent variables: Alcohol Cannabis 
Sexual 
performance 
drugs (poppers, 
EDM**) 
Party drugs 
(cocaine, 
amphetamine, 
MDMA) 
Chemsex drugs 
(GHB, ketamine, 
mephedrone)  
More than 1 
substance 
      
Last anal sex event - non-steady partner 1.45*** 1.00 1.51*** 1.26 1.57 1.40* 
Last anal sex event - more than one partner 2.32*** 1.94* 5.46*** 3.47*** 7.14*** 6.04*** 
Having ever injected drugs 1.81** 2.22** 2.03** 4.82*** 5.73*** 4.50*** 
Visiting gay venues last 3 months (≥7 times vs <7 
times) 1.69*** 1.23 1.31* 1.56** 1.24 1.32 
Being very satisfied with sexual life 0.87 0.95 1.25* 1.13 1.60 1.31 
STI diagnosis in the past 12 months 1.10 1.35 1.73*** 1.62* 2.20** 1.91*** 
_cons 1.17 0.07*** 0.08*** 0.05*** 0.00*** 0.03*** 
city (random effect variance) 1.25* 1.29 1.43* 1.46 4.8 1.66* 
 
* p<0.05; ** p<0.01; *** p<0.001 
#Mobile: any situation other than a native living in the country of birth 
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Supplementary Figure 1. The most common patterns of substance use during last sexual 
encounter associated with anal sex, by study site, Sialon II 
 
3 or more = 3 or more substance consumed 
EDM = erectile dysfunction medication 
 
